A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Varients in Healthy Individuals
Conditions: SARS-CoV-2 Infection; COVID-19 Intervention: Biological: BNT162b2 (Omi XBB.1.5) Sponsors: BioNTech SE; Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 18, 2023 Category: Research Source Type: clinical trials
Immunogenicity and Safety of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine in Healthy Volunteers
Conditions: COVID-19; Vaccines Interventions: Biological: AdCLD-CoV19-1 OMI; Biological: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran) Sponsor: Cellid Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials
Using Text Messages to Boost COVID-19 Vaccine Booking Rate
Conditions: Vaccination Hesitancy; COVID-19 Interventions: Behavioral: Behavioural science-informed text messages; Behavioral: Control Sponsors: The Behavioural Insights Team; Public Health England; Department of Health and Social Care; NHS England and NHS Improvement Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials
Immunogenicity and Safety of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine in Healthy Volunteers
Conditions: COVID-19; Vaccines Interventions: Biological: AdCLD-CoV19-1 OMI; Biological: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran) Sponsor: Cellid Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials
Using Text Messages to Boost COVID-19 Vaccine Booking Rate
Conditions: Vaccination Hesitancy; COVID-19 Interventions: Behavioral: Behavioural science-informed text messages; Behavioral: Control Sponsors: The Behavioural Insights Team; Public Health England; Department of Health and Social Care; NHS England and NHS Improvement Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials
Immunogenicity and Safety of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine in Healthy Volunteers
Conditions: COVID-19; Vaccines Interventions: Biological: AdCLD-CoV19-1 OMI; Biological: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran) Sponsor: Cellid Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials
Using Text Messages to Boost COVID-19 Vaccine Booking Rate
Conditions: Vaccination Hesitancy; COVID-19 Interventions: Behavioral: Behavioural science-informed text messages; Behavioral: Control Sponsors: The Behavioural Insights Team; Public Health England; Department of Health and Social Care; NHS England and NHS Improvement Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials
Immunogenicity and Safety of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine in Healthy Volunteers
Conditions: COVID-19; Vaccines Interventions: Biological: AdCLD-CoV19-1 OMI; Biological: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran) Sponsor: Cellid Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials
Using Text Messages to Boost COVID-19 Vaccine Booking Rate
Conditions: Vaccination Hesitancy; COVID-19 Interventions: Behavioral: Behavioural science-informed text messages; Behavioral: Control Sponsors: The Behavioural Insights Team; Public Health England; Department of Health and Social Care; NHS England and NHS Improvement Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials
